Iranian journal of pathology · 2025
The Link Between High Sensitivity Troponin T Levels and Outcomes Among Patients with Congestive Heart Failure: A Systematic Review and Meta-Analysis Study.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdollahi Alireza, Nozarian Zohreh, Salarvand Samaneh, Pourebrahimi Elham
Аннотация
BACKGROUND & OBJECTIVE: High-sensitivity cardiac troponin T (hs-cTnT) has emerged as a critical biomarker in cardiovascular diseases, particularly in congestive heart failure (CHF). This systematic review and meta-analysis aimed to assess the association between hs-cTnT levels and clinical outcomes in patients with CHF.
METHODS: A comprehensive literature search was performed across multiple databases to identify studies evaluating the relationship between hs-cTnT levels and clinical outcomes in CHF. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) for all-cause mortality, cardiovascular mortality, or cardiovascular hospitalization.
RESULTS: Elevated hs-cTnT levels were significantly associated with adverse outcomes. The pooled HR and OR for all-cause mortality were 1.70 (95% CI, 1.49-1.94) and 6.19 (95% CI, 3.88-9.86), respectively. For cardiovascular mortality, the pooled HR was 1.59 (95% CI, 1.38-1.83) and the pooled OR was 6.87 (95% CI, 3.93-12.01). For cardiovascular hospitalization, the pooled HR was 1.56 (95% CI, 1.42-1.70) and the pooled OR was 4.32 (95% CI, 2.22-8.39).
CONCLUSION: Elevated hs-cTnT levels are strongly associated with an increased risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization in patients with CHF. These findings highlight the prognostic value of hs-cTnT in the clinical management of heart failure.
METHODS: A comprehensive literature search was performed across multiple databases to identify studies evaluating the relationship between hs-cTnT levels and clinical outcomes in CHF. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) for all-cause mortality, cardiovascular mortality, or cardiovascular hospitalization.
RESULTS: Elevated hs-cTnT levels were significantly associated with adverse outcomes. The pooled HR and OR for all-cause mortality were 1.70 (95% CI, 1.49-1.94) and 6.19 (95% CI, 3.88-9.86), respectively. For cardiovascular mortality, the pooled HR was 1.59 (95% CI, 1.38-1.83) and the pooled OR was 6.87 (95% CI, 3.93-12.01). For cardiovascular hospitalization, the pooled HR was 1.56 (95% CI, 1.42-1.70) and the pooled OR was 4.32 (95% CI, 2.22-8.39).
CONCLUSION: Elevated hs-cTnT levels are strongly associated with an increased risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization in patients with CHF. These findings highlight the prognostic value of hs-cTnT in the clinical management of heart failure.